Kymera Therapeutics, Inc.

Previous wording

Our publicly disclosed oral immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. We are developing KT-621 as part of our STAT6 program, which is currently being evaluated in the BROADEN2 Phase 2b clinical trial in adult and adolescent patients with moderate to severe Atopic Dermatitis (AD) and the BREADTH Phase 2b clinical trial in adult patients with moderate to severe asthma. We are also developing KT-579 as part of our oral IRF5 degrader program, which is being evaluated in a Phase 1 clinical trial in healthy volunteers. We are collaborating with Sanofi S.A. (“Sanofi”) on the development of our IRAK4 degrader, KT-485/SAR447971, which is being evaluated in a Phase 1 clinical trial. We are also collaborating with Gilead Sciences, Inc. (“Gilead”) on the development of our oral CDK2 molecular glue degrader, KT-200, which is currently in IND-enabling studies. Our additional early undisclosed pipeline programs focus on addressing high impact targets that have been elusive to conventional modalities and that drive the pathogenesis of multiple serious diseases with significant unmet medical needs.

Current wording

Our publicly disclosed oral immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. We are developing KT-621 as part of our STAT6 program, which is currently being evaluated in the BROADEN2 Phase 2b clinical trial in adult and adolescent patients with moderate to severe Atopic Dermatitis (AD) and the BREADTH Phase 2b clinical trial in adult patients with moderate to severe asthma. As part of our oral IRF5 degrader program, we are also developing KT-579, which has completed a Phase 1 clinical trial in healthy volunteers and is expected to advance into a Phase 1b trial in lupus patients. We are collaborating with Sanofi S.A. (“Sanofi”) on the development of our IRAK4 degrader, KT-485/SAR447971, which is being evaluated in a Phase 1 clinical trial. We are also collaborating with Gilead Sciences, Inc. (“Gilead”) on the development of our oral CDK2 molecular glue degrader, KT-200, which is currently in IND-enabling studies. Our additional early undisclosed pipeline programs focus on addressing high impact targets that have been elusive to conventional modalities and that drive the pathogenesis of multiple serious diseases with significant unmet medical needs.

Previous wording

Since our inception in 2015, we have devoted substantially all our efforts to organizing and staffing our company, research and development activities, business planning, raising capital, building our intellectual property portfolio and providing general and administrative support for these operations. Through June 30, 2026, we have received gross proceeds of $2.75 billion from sales of our convertible preferred stock, the sale of common stock including our August 2020 initial public offering, or IPO, and concurrent private placement, our subsequent follow-on offerings and private placement offering, our prior sales agreement with Cowen and through our corporate collaborations.

Current wording

Since our inception in 2015, we have devoted substantially all our efforts to organizing and staffing our company, research and development activities, business planning, raising capital, building our intellectual property portfolio and providing general and administrative support for these operations. Through September 30, 2026, we have received gross proceeds of $3.03 billion from sales of our convertible preferred stock, the sale of common stock including our August 2020 initial public offering, or IPO, and concurrent private placement, our subsequent follow-on offerings and private placement offering, our sales agreements with Cowen and through our corporate collaborations.

Previous wording

We have incurred significant operating losses since inception. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current product candidates or any future product candidates. Our net losses were $311.4 million and $223.9 million for the years ended December 31, 2025 and 2024, respectively. We reported net losses of $61.2 million and $130.4 million for the three and six months ended June 30, 2026 respectively, and $76.6 million and $142.2 million for the three and six months ended June 30, 2025, respectively. In addition, as of June 30, 2026 and December 31, 2025, we had an accumulated deficit of $1,196 million and $1,066 million, respectively. We expect that our expense and capital requirements will increase substantially in connection with our ongoing activities, particularly if and as we:

Current wording

We have incurred significant operating losses since inception. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current product candidates or any future product candidates. Our net losses were $311.4 million and $223.9 million for the years ended December 31, 2025 and 2024, respectively. We reported net losses of $132.0 million and $262.4 million for the three and nine months ended September 30, 2026 respectively, and $82.2 million and $224.4 million for the three and nine months ended September 30, 2025, respectively. In addition, as of September 30, 2026 and December 31, 2025, we had an accumulated deficit of $1,328 million and $1,066 million, respectively. We expect that our expense and capital requirements will increase substantially in connection with our ongoing activities, particularly if and as we:

Previous wording

As of June 30, 2026, we had cash, cash equivalents and marketable securities of $1,505 million. We believe the existing cash, cash equivalents and marketable securities on hand will be sufficient to fund our operations into 2029, beyond multiple clinical inflection points in our pipeline. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See “Liquidity and capital resources” below.

Current wording

As of September 30, 2026, we had cash, cash equivalents and marketable securities of $1,646 million. We believe the existing cash, cash equivalents and marketable securities on hand will be sufficient to fund our operations into 2029, beyond multiple clinical inflection points in our pipeline. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See “Liquidity and capital resources” below.

Previous wording

On June 25, 2025, we entered into an exclusive option and license agreement (the “Gilead Agreement”) with Gilead Sciences, Inc. (“Gilead”), to collaborate on developing novel molecular glue degraders directed against cyclin-dependent kinase 2 (“CDK2”). Under the Gilead Agreement, the Company granted to Gilead an exclusive option, exercisable during a defined option period, to exercise an exclusive, worldwide license to develop, manufacture, and commercialize certain CDK2 degraders generated under the collaboration.

Current wording

On June 25, 2025, we entered into an exclusive option and license agreement (the “Gilead Agreement”) with Gilead Sciences, Inc. (“Gilead”), to collaborate on developing novel molecular glue degraders directed against cyclin-dependent kinase 2 (“CDK2”). Under the Gilead Agreement, we granted to Gilead an exclusive option, exercisable during a defined option period, to exercise an exclusive, worldwide license to develop, manufacture, and commercialize certain CDK2 degraders generated under the collaboration.

Previous wording

Pursuant to the Gilead Agreement, the Company was responsible for all discovery and preclinical research activities through the delivery of a complete data package as defined in the agreement. After receiving the complete data package, Gilead exercised its option to license the program and now has global rights to develop, manufacture and commercialize all products resulting from the collaboration.

Current wording

Pursuant to the Gilead Agreement, we were responsible for all discovery and preclinical research activities through the delivery of a complete data package as defined in the agreement. After receiving the complete data package, Gilead exercised its option to license the program and now has global rights to develop, manufacture and commercialize all products resulting from the collaboration.

Previous wording

Collaboration revenues were $65.0 million and $11.5 million for the three months ended June 30, 2026 and 2025, respectively. All of the revenue recognized for the three months ended June 30, 2026 is attributable to payments achieved under our collaboration agreements with Gilead and Sanofi. All of the revenue recognized for the three months ended June 30, 2025 is attributable to our collaboration agreement with Sanofi.

Current wording

Collaboration revenues were $0 and $2.8 million for the three months ended September 30, 2026 and 2025, respectively. All of the revenue recognized for the three months ended September 30, 2025 is attributable to payments achieved under our collaboration agreements with Gilead.

Previous wording

Research and development expenses were $119.5 million for the three months ended June 30, 2026, compared to $78.4 million for the three months ended June 30, 2025. The increase of $41.1 million was primarily due to a $23.5 million increase in costs related to our STAT6 program, a $8.9 million increase in personnel, equity-based compensation, occupancy, and other internal costs due to increased investment in employee talent and facilities in the research and development functions, and a $8.7 million increase in activities related to our non-STAT6 programs.

Current wording

Research and development expenses were $128.5 million for the three months ended September 30, 2026, compared to $74.1 million for the three months ended September 30, 2025. The increase of $54.4 million was primarily due to a $34.7 million increase in costs related to our STAT6 program, a $10.7 million increase in personnel, equity-based compensation, occupancy, and other internal costs due to increased investment in employee talent and facilities in the research and development functions, and a $9.1 million increase in activities related to our non-STAT6 programs.

Previous wording

General and administrative expenses were $21.1 million for the three months ended June 30, 2026, compared to $17.6 million for the three months ended June 30, 2025. This increase of $3.5 million was primarily due to an increase in legal and professional service fees, personnel, facility, occupancy, and other expenses to support our growth. Equity-based compensation expenses included in general and administrative expenses were $8.6 million and $7.4 million for the three months ended June 30, 2026 and 2025, respectively.

Current wording

General and administrative expenses were $18.7 million for the three months ended September 30, 2026, compared to $17.3 million for the three months ended September 30, 2025. This increase of $1.4 million was primarily due to an increase in legal and professional service fees, personnel, facility, occupancy, and other expenses to support our growth. Equity-based compensation expenses included in general and administrative expenses were $7.9 million and $7.4 million for the three months ended September 30, 2026 and 2025, respectively.

Previous wording

Other income, net was $14.4 million for the three months ended June 30, 2026, compared to $7.9 million for the three months ended June 30, 2025. The $6.5 million increase was primarily due to an increase in the cash, cash equivalents, and marketable securities balances resulting in higher interest income.

Current wording

Other income, net was $15.2 million for the three months ended September 30, 2026, compared to $10.3 million for the three months ended September 30, 2025. The $4.9 million increase was primarily due to an increase in the cash, cash equivalents, and marketable securities balances resulting in higher interest income.

Previous wording

The following table summarizes our results of operations for the six months ended June 30, 2026 and 2025:

Current wording

The following table summarizes our results of operations for the nine months ended September 30, 2026 and 2025:

Previous wording

Collaboration revenues were $99.4 million and $33.6 million for the six months ended June 30, 2026 and 2025, respectively. The revenue recognized for the six months ended June 30, 2026 is attributable to our collaboration agreements with Gilead and Sanofi. All of the revenue recognized for the six months ended June 30, 2025 is attributable to our collaboration agreement with Sanofi.

Current wording

Collaboration revenues were $99.4 million and $36.3 million for the nine months ended September 30, 2026 and 2025, respectively. The revenue recognized for the nine months ended September 30, 2026 and September 30, 2025 is attributable to our collaboration agreements with Gilead and Sanofi.

Previous wording

Research and development expenses were $217.6 million for the six months ended June 30, 2026, compared to $158.6 million for the six months ended June 30, 2025. The increase of $59.0 million was primarily due to a $36.1 million increase in costs related to our STAT6 program, a $15.6 million increase in personnel, equity-based compensation, occupancy, and other internal costs due to increased investment in employee talent and facilities in the research and development functions, and a $7.3 million increase in activities related to our non-STAT6 programs.

Current wording

Research and development expenses were $346.2 million for the nine months ended September 30, 2026, compared to $232.7 million for the nine months ended September 30, 2025. The increase of $113.4 million was primarily due to a $70.7 million increase in costs related to our STAT6 program, a $26.3 million increase in personnel, equity-based compensation, occupancy, and other internal costs due to increased investment in employee talent and facilities in the research and development functions, and a $16.4 million increase in activities related to our non-STAT6 programs.

Previous wording

General and administrative expenses were $41.5 million for the six months ended June 30, 2026, compared to $33.9 million for the six months ended June 30, 2025. This increase of $7.6 million was primarily due to an increase in legal and professional service fees, personnel, facility, occupancy, and other expenses to support our growth. Equity-based compensation expenses included in general and administrative expenses were $16.0 million and $14.1 million for the six months ended June 30, 2026 and 2025, respectively.

Current wording

General and administrative expenses were $60.2 million for the nine months ended September 30, 2026, compared to $51.3 million for the nine months ended September 30, 2025. This increase of $8.9 million was primarily due to an increase in legal and professional service fees, personnel, facility, occupancy, and other expenses to support our growth. Equity-based compensation expenses included in general and administrative expenses were $23.9 million and $21.5 million for the nine months ended September 30, 2026 and 2025, respectively.

Previous wording

Other income, net was $29.3 million for the six months ended June 30, 2026, compared to $16.8 million for the six months ended June 30, 2025. The $12.5 million increase was primarily due to an increase in the cash, cash equivalents, and marketable securities balances resulting in higher interest income.

Current wording

Other income, net was $44.6 million for the nine months ended September 30, 2026, compared to $27.1 million for the nine months ended September 30, 2025. The $17.5 million increase was primarily due to an increase in the cash, cash equivalents, and marketable securities balances resulting in higher interest income.

Previous wording

We have not yet generated any revenue from any product sales, and we have incurred significant operating losses since our inception. We have not yet commercialized any products and we do not expect to generate revenue from sales of products for several years, if at all. Through June 30, 2026, we have received gross proceeds of $2.75 billion from sales of our convertible preferred stock, the sale of common stock including our August 2020 initial public offering, or IPO, and concurrent private placement, our follow-on offerings and private placement offering, our prior sales agreement with TD Securities (USA) LLC, or Cowen, and through our corporate collaborations. As of June 30, 2026, we had cash and cash equivalents and marketable securities of $1,505 million.

Current wording

We have not yet generated any revenue from any product sales, and we have incurred significant operating losses since our inception. We have not yet commercialized any products and we do not expect to generate revenue from sales of products for several years, if at all. Through September 30, 2026, we have received gross proceeds of $3.03 billion from sales of our convertible preferred stock, the sale of common stock including our August 2020 initial public offering, or IPO, and concurrent private placement, our follow-on offerings and private placement offering, our sales agreements with Cowen and through our corporate collaborations. As of September 30, 2026, we had cash and cash equivalents and marketable securities of $1,646 million.

Previous wording

On February 26, 2026, we entered into a sales agreement, or Cowen Sales Agreement, with Cowen, pursuant to which we may offer and sell shares of our common stock having aggregate gross proceeds of up to $500.0 million from time to time in “at-the-market” offerings through Cowen, as our sales agent. We agreed to pay Cowen a commission of up to 3.0% of the gross proceeds of any shares sold by Cowen under the Cowen Sales Agreement. As of June 30, 2026, we have not sold any shares of common stock under the Cowen Sales Agreement.

Current wording

On February 26, 2026, we entered into a sales agreement, or Cowen Sales Agreement, with Cowen, pursuant to which we may offer and sell shares of our common stock having aggregate gross proceeds of up to $500.0 million from time to time in “at-the-market” offerings through Cowen, as our sales agent. We agreed to pay Cowen a commission of up to 3.0% of the gross proceeds of any shares sold by Cowen under the Cowen Sales Agreement. As of September 30, 2026 we have sold 2,032,140 shares of common stock under the Cowen Sales Agreement resulting in gross proceeds of approximately $219.9 million.

Previous wording

During the six months ended June 30, 2026, cash used in operating activities was $142.9 million, primarily resulting from our net loss of $130.4 million during the period and a $46.4 million net decrease in other operating assets and liabilities primarily driven by changes in contract assets, deferred revenue, accounts payable, accrued expenses and operating lease liabilities. This was partially offset by adjustments for non-cash items of $33.9 million primarily consisting of stock-based compensation, depreciation & amortization and premiums & discounts on available-for sale-securities.

Current wording

During the nine months ended September 30, 2026, cash used in operating activities was $220.8 million, primarily resulting from our net loss of $262.4 million during the period and a $11.6 million net decrease in other operating assets and liabilities primarily driven by changes in contract assets, deferred revenue, accounts payable, accrued expenses and operating lease liabilities. This was partially offset by adjustments for non-cash items of $53.2 million primarily consisting of stock-based compensation, depreciation & amortization and premiums & discounts on available-for sale-securities.

Previous wording

During the six months ended June 30, 2025, cash used in operating activities was $139.0 million, primarily resulting from our net loss of $142.2 million during the period and a $26.0 million net decrease in other operating assets and liabilities primarily driven by changes in contract assets, deferred revenue, accounts payable, accrued expenses and operating lease liabilities. This was partially offset by adjustments for non-cash items of $29.1 million (primarily consisting of stock-based compensation, depreciation & amortization and premiums & discounts on available-for-sale securities).

Current wording

During the nine months ended September 30, 2025, cash used in operating activities was $166.1 million, primarily resulting from our net loss of $224.4 million during the period partially offset by a $9.5 million net increase in other operating assets and liabilities primarily driven by changes in contract assets, deferred revenue, accounts payable, accrued expenses and operating lease liabilities as well as adjustments for non-cash items of $48.8 million (primarily consisting of stock-based compensation, lease impairment, depreciation & amortization and premiums & discounts on available-sale-securities).

Previous wording

During the six months ended June 30, 2026, cash used in investing activities was $122.8 million comprised of purchases of marketable securities of $390.9 million, partially offset by maturities of marketable securities of $269.0 million and purchases of property and equipment of $0.9 million.

Current wording

During the nine months ended September 30, 2026, cash used in investing activities was $21.2 million comprised of purchases of marketable securities of $451.6 million, partially offset by maturities of marketable securities of $431.6 million and purchases of property and equipment of $1.2 million.

Previous wording

During the six months ended June 30, 2025, cash provided by investing activities was $108.6 million comprised of maturities of marketable securities of $251.7 million, partially offset by purchases of marketable securities of $141.9 million and purchases of property and equipment of $1.2 million.

Current wording

During the nine months ended September 30, 2025, cash used in investing activities was $126.7 million comprised of purchases of marketable securities of $509.5 million and purchases of property and equipment of $1.3 million, partially offset by maturities of marketable securities of $384.1 million.

Previous wording

During the six months ended June 30, 2026, net cash provided by financing activities was $33.2 million, consisting of $32.6 million in proceeds from the exercise of employee stock options and $1.5 million from issuance of shares under our employee stock purchase plan, partially offset by finance lease payments of $0.9 million.

Current wording

During the nine months ended September 30, 2026, net cash provided by financing activities was $258.8 million, consisting of $215.4 million in net proceeds from the issuance of common stock through at-the-market sales agreement, $43.2 million in proceeds from the exercise of employee stock options and $1.5 million from issuance of shares under our employee stock purchase plan, partially offset by finance lease payments of $1.3 million.

Previous wording

During the six months ended June 30, 2025, net cash provided by financing activities was $246.0 million, consisting of $237.3 million in proceeds from the issuance of common stock and accompanying pre-funded warrants, net of offering costs, $8.2 million in proceeds from the exercise of employee stock options, $1.1 million of proceeds from our employee stock purchase plan, partially offset by finance lease payments of $0.7 million.

Current wording

During the nine months ended September 30, 2025, net cash provided by financing activities was $285.5 million, consisting of $272.7 million in proceeds from the issuance of common stock and accompanying pre-funded warrants, net of offering costs, $12.8 million in proceeds from the exercise of employee stock options, $1.1 million of proceeds from our employee stock purchase plan, partially offset by finance lease payments of $1.1 million.

Previous wording

We believe the existing cash, cash equivalents and marketable securities of $1,505 million as of June 30, 2026, will enable us to fund our operating expenses and capital expenditure requirements into 2029. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. We expect that we will require additional funding to continue the clinical development of our clinical programs, commercialize our product candidates if we receive regulatory approval, and pursue in-licenses or acquisitions of other product candidates. If we receive regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize our product candidates.

Current wording

We believe the existing cash, cash equivalents and marketable securities of $1,646 million as of September 30, 2026, will enable us to fund our operating expenses and capital expenditure requirements into 2029. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. We expect that we will require additional funding to continue the clinical development of our clinical programs, commercialize our product candidates if we receive regulatory approval, and pursue in-licenses or acquisitions of other product candidates. If we receive regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize our product candidates.

Previous wording

As of June 30, 2026, we had outstanding pre-funded warrants to purchase 15,815,253 shares of common stock, each with an exercise price of $0.0001 per share. These warrants can be exercised at any time at the discretion of the holders, subject to certain ownership limitations. While the potential exercise of these pre-funded warrants would result in the issuance of additional shares, thus increasing the total shares outstanding, their nominal exercise price means they are already considered outstanding for purposes of calculating our weighted average common stock outstanding and earnings per share. Due to the minimal exercise price, we do not anticipate significant additional cash proceeds upon exercise and consequently does not expect the exercise of these warrants to materially affect its liquidity, capital resources, or overall financial condition.

Current wording

As of September 30, 2026, we had outstanding pre-funded warrants to purchase 15,815,253 shares of common stock, each with an exercise price of $0.0001 per share. These warrants can be exercised at any time at the discretion of the holders, subject to certain ownership limitations. While the potential exercise of these pre-funded warrants would result in the issuance of additional shares, thus increasing the total shares outstanding, their nominal exercise price means they are already considered outstanding for purposes of calculating our weighted average common stock outstanding and earnings per share. Due to the minimal exercise price, we do not anticipate significant additional cash proceeds upon exercise and consequently does not expect the exercise of these warrants to materially affect liquidity, capital resources, or overall financial condition.

Previous wording

Our management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. During the six months ended June 30, 2026, there were no material changes to our critical accounting policies from those described in our Annual Report Form 10-K filed with the SEC on February 26, 2026.

Current wording

Our management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. During the nine months ended September 30, 2026, there were no material changes to our critical accounting policies from those described in our Annual Report Form 10-K filed with the SEC on February 26, 2026.